Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Type 1 Diabetes
Interventions
DRUG

67.5 mg oral insulin crystals daily

human insulin crystals in capsules

DRUG

500mg oral insulin crystals every other week

human insulin crystals in capsules

Trial Locations (19)

3050

Walter and Eliza Hall Institute of Medical Research, Parkville

10032

Columbia University-Naomi Berrie Diabetes Center, New York

15224

University of Pittsburgh, Pittsburgh

30322

Emory Children's Center, Atlanta

32610

University of Florida, Gainesville

33136

University of Miami, Miami

33612

University of South Florida, Tampa

37232

Vanderbilt University, Nashville

46202

Indiana University-Riley Hospital for Children, Indianapolis

60637

University of Chicago, Chicago

75390

University of Texas Southwestern, Dallas

77030

Baylor College of Medicine, Houston

80109

Barbara Davis Center for Childhood Diabetes, Aurora

94305

Stanford University, Stanford

98101

Benaroya Research Institute, Seattle

94158-2549

University of California - San Francisco, San Francisco

02215

Joslin Diabetes Center, Boston

Unknown

The Hospital for Sick Children, Toronto

San Raffaele Hospital, Milan

All Listed Sponsors
collaborator

Type 1 Diabetes TrialNet

NETWORK

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02580877 - Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20) | Biotech Hunter | Biotech Hunter